BMI View: Sweden’s epidemiological profile will continue to be attractive to manufacturers of medicines
for non-communicable diseases. Despite the relative rapid uptake of innovative pharmaceuticals, the
burden of chronic conditions will increase over the next 15 years. Presenting a challenge to drugmakers,
like many other developed states, Sweden is introducing cost-containment measures to restrict the
commercial opportunities available to drugmakers.
Headline Expenditure Projections
? Pharmaceuticals: SEK39.50bn (USD4.68bn) in 2015 to SEK39.79bn (USD4.68bn) in 2016; +0.74% in
local currency terms and -0.1% in US dollar terms.
? Healthcare: SEK371.82bn (USD44.09bn) in 2015 to SEK381.68bn (USD44.88bn) in2016; +2.7% in
local currency terms and 1.8% in US dollar terms.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Sweden 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 21
OTC Medicine Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Sweden 2014-2020) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2014-2020) 25
Industry Risk/Reward Index 26
Western Europe Risk/Reward Index 26
Sweden Risk/Reward Index 31
Rewards 31
Risks 31
Regulatory Review 33
Intellectual Property Issues 34
Pricing Regime 35
Reimbursement Regime 36
Market Overview 38
Healthcare Sector 38
Table: Healthcare Resources (Sweden 2010-2015) 41
Table: Healthcare Personnel (Sweden 2010-2015) 41
Table: Healthcare Activity (Sweden 2010-2015) 42
Research & Development 42
Table: Drug Development Member Companies of SwedenBIO, 2015 43
Clinical Trials 44
Epidemiology 45
Competitive Landscape 49
Research-Based Industry 49
Table: Multinational Market Activity 51
Pharmaceutical Distribution 52
Pharmaceutical Retail Sector 53
Company Profile 54
AstraZeneca 54
Meda 59
Medivir 63
Novartis 68
Swedish Orphan Biovitrum (SOBI) 71
Demographic Forecast 77
Table: Population Headline Indicators (Sweden 1990-2025) 78
Table: Key Population Ratios (Sweden 1990-2025) 78
Table: Urban/Rural Population & Life Expectancy (Sweden 1990-2025) 79
Table: Population By Age Group (Sweden 1990-2025) 79
Table: Population By Age Group % (Sweden 1990-2025) 80
Glossary 82
Methodology 84
Pharmaceutical Expenditure Forecast Model 84
Healthcare Expenditure Forecast Model 84
Notes On Methodology 85
Risk/Reward Index Methodology 86
Index Overview 87
Table: Pharmaceutical Risk/Reward Index Indicators 87
Indicator Weightings 88

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Sweden 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Sweden 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2014-2020)
Table: Healthcare Resources (Sweden 2010-2015)
Table: Healthcare Personnel (Sweden 2010-2015)
Table: Healthcare Activity (Sweden 2010-2015)
Table: Drug Development Member Companies of SwedenBIO, 2015
Table: Multinational Market Activity
Table: Population Headline Indicators (Sweden 1990-2025)
Table: Key Population Ratios (Sweden 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Sweden 1990-2025)
Table: Population By Age Group (Sweden 1990-2025)
Table: Population By Age Group % (Sweden 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators